{"disease":{"id":"renal-transplant-rejection","name":"Renal transplant rejection","therapeutic_area":"","data":{},"enrichment_level":0,"last_enriched_at":null,"visit_count":0,"created_at":"2026-04-19T18:31:21.150Z","updated_at":"2026-04-19T18:39:44.960Z","meddra_pt":null,"meddra_code":null,"icd10_codes":null,"synonyms":[],"prevalence_global":null,"prevalence_us":null,"marketed_drug_count":10,"pipeline_drug_count":0,"trial_count":0},"drugs":{"marketed":[{"drug_id":"tacrolimus","indication_name":"Renal transplant rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Prograf","generic_name":"TACROLIMUS","company_name":"Astellas Pharma","drug_phase":"marketed","molecular_target":"Interferon gamma","drug_class":"Calcineurin Inhibitor Immunosuppressant","quality_score":80,"revenue":"1600","mechanism":"Prograf works by inhibiting the activation of T-lymphocytes, a type of immune cell."},{"drug_id":"basiliximab","indication_name":"Renal transplant rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Chrft5","generic_name":"BASILIXIMAB","company_name":"Novartis","drug_phase":"marketed","molecular_target":"Interleukin-2 receptor subunit alpha","drug_class":"Interleukin-2 Receptor Blocking Antibody [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"imlifidase","indication_name":"Renal transplant rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ides","generic_name":"IMLIFIDASE","company_name":"Hansa Biopharma AB","drug_phase":"marketed","molecular_target":"Immunoglobulin gamma (IgG), heavy chain","drug_class":"","quality_score":20,"revenue":null,"mechanism":""},{"drug_id":"muromonab","indication_name":"Renal transplant rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Muromonab","company_name":"St. Jude Children's Research Hospital","drug_phase":"phase_2","molecular_target":"T-cell surface glycoprotein CD3","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"belatacept","indication_name":"Renal transplant rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nulojix","generic_name":"BELATACEPT","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"T-lymphocyte activation antigen CD80","drug_class":"Selective T Cell Costimulation Blocker [EPC]","quality_score":52,"revenue":null,"mechanism":"Nulojix blocks the activation of T cells by binding to CD80, preventing an immune response."},{"drug_id":"muromonab-cd3","indication_name":"Renal transplant rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Orthoclone Okt3","generic_name":"MUROMONAB-CD3","company_name":"Ortho Biotech","drug_phase":"marketed","molecular_target":"T-cell surface glycoprotein CD3","drug_class":"CD3 Blocker Immunosuppressant","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"daclizumab","indication_name":"Renal transplant rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zenapax","generic_name":"DACLIZUMAB","company_name":"Hoffman-La Roche","drug_phase":"marketed","molecular_target":"Interleukin-2 receptor","drug_class":"Interleukin-2 Receptor Blocking Antibody","quality_score":21,"revenue":null,"mechanism":""},{"drug_id":"nulojix","indication_name":"Renal transplant rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Nulojix","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"T-lymphocyte activation antigen CD80, T-lymphocyte activation antigen CD86","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"simulect","indication_name":"Renal transplant rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Simulect","company_name":"Astellas Pharma Inc","drug_phase":"marketed","molecular_target":"Interleukin-2 receptor subunit alpha","drug_class":"","quality_score":13,"revenue":null,"mechanism":null},{"drug_id":"zenapax","indication_name":"Renal transplant rejection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Zenapax","company_name":"National Institute of Neurological Disorders and Stroke (NINDS)","drug_phase":"phase_3","molecular_target":"Interleukin-2 receptor","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":10,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT02727296","title":"Volatile Anesthetic Protection Of Renal Transplants 2","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":488,"lead_sponsor_name":"University Medical Center Groningen","has_results":false},{"nct_id":"NCT03719339","title":"VIRTUUS Children's Study","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":445,"lead_sponsor_name":"Children's Hospital of Philadelphia","has_results":false},{"nct_id":"NCT06025240","title":"Expanding the Scope of Post-transplant HLA-specific Antibody Detection and Monitoring in Renal Transplant Recipients","phase":"","overall_status":"RECRUITING","enrollment_count":282,"lead_sponsor_name":"Liverpool University Hospitals NHS Foundation Trust","has_results":false},{"nct_id":"NCT05756036","title":"Torque Teno Virus: A Biomarker of Immunosuppression","phase":"","overall_status":"COMPLETED","enrollment_count":268,"lead_sponsor_name":"Queen Mary University of London","has_results":false},{"nct_id":"NCT05385432","title":"Induction in Sensitized Kidney Transplant Recipients Without Pre-existing Donor-specific antiboDies","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":244,"lead_sponsor_name":"University Hospital, Tours","has_results":false},{"nct_id":"NCT03140514","title":"Urine CXCL10 Chemokine Monitoring Post-renal Transplant","phase":"NA","overall_status":"COMPLETED","enrollment_count":241,"lead_sponsor_name":"University Hospital, Basel, Switzerland","has_results":false},{"nct_id":"NCT02866682","title":"Prospective Study Comparing Brand and Generic Immunosuppression on Transplant Outcomes, Adherence, & Immune Response in Kidney Transplant Recipients","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":176,"lead_sponsor_name":"University of California, Los Angeles","has_results":true},{"nct_id":"NCT03192007","title":"Multi-Parametric MRI for Renal Transplantation","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":140,"lead_sponsor_name":"University of Minnesota","has_results":false},{"nct_id":"NCT07508787","title":"A Study Comparing Siplizumab With Rabbit Anti-Thymocyte Globulin to Help the Body Accept a Kidney Transplant","phase":"PHASE2","overall_status":"NOT_YET_RECRUITING","enrollment_count":120,"lead_sponsor_name":"Nefro Avillion Clinical Development, LLC","has_results":false},{"nct_id":"NCT07053462","title":"CRISPR-Edited HLA Donor Kidney Transplant to Reduce Rejection Risk","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":90,"lead_sponsor_name":"AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC","has_results":false},{"nct_id":"NCT02738918","title":"Belatacept (Nulojix) in Renal Transplant Recipient With Mild Immunologic Risk Factor: a Pilot Prospective Study.","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":51,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT03511560","title":"Envarsus on the Effect of Total Tacrolimus Dose/Trough Level Ratio on Renal Function (eGFR) in Kidney Transplantation","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":50,"lead_sponsor_name":"Columbia University","has_results":true},{"nct_id":"NCT03646344","title":"Heme Arginate in Transplantation Study","phase":"PHASE3","overall_status":"TERMINATED","enrollment_count":47,"lead_sponsor_name":"University of Edinburgh","has_results":false},{"nct_id":"NCT03780101","title":"Pathology and Imaging in Kidney Allografts","phase":"","overall_status":"TERMINATED","enrollment_count":29,"lead_sponsor_name":"NHS Greater Glasgow and Clyde","has_results":false},{"nct_id":"NCT03317925","title":"Renal Transplant Injury and the Renin-Angiotensin System in Kids (RETASK)","phase":"","overall_status":"COMPLETED","enrollment_count":29,"lead_sponsor_name":"Wake Forest University Health Sciences","has_results":false},{"nct_id":"NCT03512431","title":"Dose Adjustment of Tacrolimus Based on Home Sampling in Renal Transplant Recipients","phase":"","overall_status":"COMPLETED","enrollment_count":27,"lead_sponsor_name":"Oslo University Hospital","has_results":false},{"nct_id":"NCT02006108","title":"Imaging Kidney Transplant Rejection Using Ferumoxytol-Enhanced Magnetic Resonance","phase":"NA","overall_status":"COMPLETED","enrollment_count":21,"lead_sponsor_name":"Stanford University","has_results":true},{"nct_id":"NCT03380962","title":"Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":20,"lead_sponsor_name":"Stanley Jordan, MD","has_results":false},{"nct_id":"NCT04530630","title":"Switch to Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/F/TAF) After Renal Transplant","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Weill Medical College of Cornell University","has_results":true},{"nct_id":"NCT03705091","title":"MRI in Renal Transplantation","phase":"","overall_status":"UNKNOWN","enrollment_count":20,"lead_sponsor_name":"NHS Greater Glasgow and Clyde","has_results":false},{"nct_id":"NCT03859388","title":"Longitudinal Changes in Donor-Derived Cell-Free DNA With Tocilizumab Treatment for Chronic Antibody-Mediated Rejection","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":10,"lead_sponsor_name":"Cedars-Sinai Medical Center","has_results":false},{"nct_id":"NCT02733029","title":"Contrast Enhanced Ultrasonography to Detect Human Renal Transplant Rejection","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":8,"lead_sponsor_name":"Brigham and Women's Hospital","has_results":false},{"nct_id":"NCT03991780","title":"Fostamatinib in the Treatment of Chronic Active Antibody Mediated Rejection","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":8,"lead_sponsor_name":"Imperial College London","has_results":false},{"nct_id":"NCT05073822","title":"NOMINATE/ Minimisation of Immunosuppression in Kidney Transplantation","phase":"PHASE1, PHASE2","overall_status":"WITHDRAWN","enrollment_count":0,"lead_sponsor_name":"University College, London","has_results":false}],"total":24},"guidelines":[],"source":"Drug Landscape verified database"}